Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243298 | 0.94 | DRD2 (0.48) | DRD2HTR1AHTR2A | |
| SCHEMBL1244021 | 0.90 | DRD2 (0.51) | DRD2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL293643 | 0.90 | HTR2A (0.50) | DRD2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL4660923 | 0.86 | HTR2A (0.47) | DRD2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL512150 | 0.82 | DRD2 (0.49) | DRD2HTR1AHTR2A | |
| SCHEMBL1243266 | 0.82 | HTR2A (0.52) | DRD2HTR2A | |
| SCHEMBL1243277 | 0.82 | HTR2A (0.51) | DRD2HTR2A | |
| SCHEMBL294062 | 0.81 | HTR2A (0.53) | DRD2HTR1AHTR2A | |
| SCHEMBL293387 | 0.81 | DRD2 (0.53) | DRD2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL2702238 | 0.80 | HTR2A (0.55) | DRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919907-B9 | HETEROCYCLIC COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-01-18 | — | — | EP | claimed |
| US-8071600-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-06 | — | — | US | claimed |
| EP-1919907-B1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2011-02-23 | — | — | EP | claimed |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | GRIN2C, GRIN2B, PMP22 | DRD2 139/4885HTR1A 29/4885HTR2A 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.